Согласно недавнему пресс-релизу биофармацевтической компании NFlection Therapeutics, Inc. («NFlection»), FDA присвоило лекарству-кандидату NFX-179 статус Орфанного Лекарства. В целом, это лечение предназначено для пациентов с кожным нейрофиброматозом 1 типа (NF1). Обозначение…
Nosotroscreemos que lospacientes de enfermedadesraras son personas, no undiagnóstico. A través de la educación, conciencia, y unpoco de humor — ayudamospacientes, suscuidadores y simpatizantesbrindándolesnoticias e historiasrelevantesya menudo inspiradoras.
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
